You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 146 No. 9, September 1986 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  CLINICAL OBSERVATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Cushing's Syndrome From the Therapeutic Use of Intramuscular Dexamethasone Acetate

Joseph M. Hughes, MD; Martin Hichens, PhD; George W. Booze, MD; Michael O. Thorner, MB

Arch Intern Med. 1986;146(9):1848-1849.


Abstract



• We present, to our knowledge, the first case of Cushing's syndrome due to large doses of intramuscular dexamethasone acetate. Dexamethasone levels after intramuscular dexamethasone administration were measured in two patients. Serial determination of the dexamethasone levels demonstrated prolonged serum half-lives of seven and 33 days in the two patients, respectively. Furthermore, pharmacologic levels of dexamethasone were present as long as seven months after the initial injections. The present recommendation for the use of intramuscular dexamethasone acetate is as frequent as every one to three weeks. However, our patients demonstrate that supraphysiologic levels of dexamethasone may still be present well beyond the three-week period.

(Arch Intern Med 1986;146:1848-1849)



Author Affiliations



From the Department of Internal Medicine, University of Virginia Medical Center, Charlottesville (Drs Hughes and Thorner); the Merck Institute for Therapeutic Research, West Point, Pa (Dr Hichens); and the Brookside Medical Center, Kingsport, Tenn (Dr Booze).


Footnotes



Accepted for publication April 28, 1986.

Reprint requests to the Department of Internal Medicine, University of Virginia Medical Center, Box 511, Charlottesville, VA 22908 (Dr Hughes).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.